Anti-Kir2.1/KCNJ2 antibody [EPR4530],Abcam,AB109750
Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Human
Application
WB, IHC-P, ICC/IF
Platform ID
BAB177825161
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it (PubMed : 36149965, PubMed : 7590287, PubMed : 9490857). Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages (PubMed : 7590287, PubMed : 7696590). The inward rectification is mainly due to the blockage of outward current by internal magnesium (PubMed : 9490857). Can be blocked by extracellular barium or cesium (PubMed : 7590287, PubMed : 7696590). Probably participates in establishing action potential waveform and excitability of neuronal and muscle tissues (PubMed : 7590287, PubMed : 7696590, PubMed : 7840300). See full target information KCNJ2
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.